Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in patients with sepsis
IRCT20231017059748N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing Colchicine + standard treatment with Placebo + standard treatment (2 arms). Primary endpoints: Interleukin-6 level, C-reactive protein and 10 more. Started Oct 2024; status: completed.
02
Drugs
colchicine
03
Conditions
sepsis
Beyond the preview
Go deeper on IRCT20231017059748N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231017059748N1.